An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

University of Kansas40 enrolled

Overview

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products (PCNA, cyclin-D1, ER alpha, PR, pS2, 450 aromatase, bcl-2, bax, caspase-3, and VEGFR) that may be useful as predictors or indicators of response to letrozole

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Interventions

letrozole 2.5 mgDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast * on hormone replacement therapy * postmenopausal * increased risk of developing breast cancer based on personal or family history * never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months * women who have a high risk of breast cancer * older than 18 years Exclusion Criteria: * no anticoagulants * no marked breast tenderness * not pregnant or within twelve months of breast feeding/childbirth

Locations (1)

University of Kansas Medical Center

Kansas City, Kansas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.